In Brief: Taro Pharmaceuticals
This article was originally published in The Rose Sheet
Executive Summary
Taro Pharmaceuticals: FDA approves the company's ANDA for prescription and OTC clotrimazole 1% solution, a topical antifungal comparable to Schering-Plough's Lotrimin athlete's foot treatment, the private-label manufacturer announced July 30. The approval is Taro's fourth this year, the company noted...